Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

10/4/2025

Janusmed sex and gender

Janusmed sex and gender – vilanterol trifenatate

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
B B
B B

Vilanterol testing environment

Vilanterol

Class : B

  1. Nationella riktlinjer för vård vid astma och kroniskt obstruktiv lungsjukdom (KOL). Socialstyrelsen. [updated 2018-01-29, cited 2020-09-14].
  2. Dharmage SC, Perret JL, Custovic A. Epidemiology of Asthma in Children and Adults. Front Pediatr. 2019;7:246.
  3. Dales RE, Mehdizadeh A, Aaron SD, Vandemheen KL, Clinch J. Sex differences in the clinical presentation and management of airflow obstruction. Eur Respir J. 2006;28:319-22.
  4. Tantisira KG, Colvin R, Tonascia J, Strunk RC, Weiss ST, Fuhlbrigge AL et al. Airway responsiveness in mild to moderate childhood asthma: sex influences on the natural history. Am J Respir Crit Care Med. 2008;178:325-31.
  5. Revinty Ellipta (vilanterol). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2019-05-21, cited 2020-08-07]
  6. Siederer S, Allen A, Yang S. Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease. Eur J Drug Metab Pharmacokinet. 2016;41(6):743-758.
  7. Food and Drug Adinistration (FDA). Prescribing information - ANORO ELLIPTA (umeclidinium and vilanterol). Drugs@FDA [www]. [updated 2013-12-01, cited 2020-09-30].
  8. Oliver A, VanBuren S, Allen A, Hamilton M, Tombs L, Kempsford R et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vilanterol, a Novel Inhaled Long-Acting β-Agonist, in Children Aged 5-11 Years with Persistent Asthma: A Randomized Trial. Clin Pharmacol Drug Dev. 2014;3(3):215-221.
  9. Oliver A, VanBuren S, Allen A, Hamilton M, Tombs L, Inamdar A et al. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma. Clin Ther. 2014;36(6):928-939e1.
  10. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]